
Ke-hung Tsui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2305342/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Caffeic acid phenethyl ester inhibits the growth of bladder carcinoma cells by upregulating growth differentiation factor 15. Biomedical Journal, 2022, 45, 763-775.	3.1	9
2	The Antitumor Effect of Caffeic Acid Phenethyl Ester by Downregulating Mucosa-Associated Lymphoid Tissue 1 via AR/p53/NF-κB Signaling in Prostate Carcinoma Cells. Cancers, 2022, 14, 274.	3.7	8
3	Comparison of Outcome and Quality of Life Between Thulium Laser (VelaTM XL) Enucleation of Prostate and Bipolar Transurethral Enucleation of the Prostate (B-TUEP). Therapeutics and Clinical Risk Management, 2022, Volume 18, 145-154.	2.0	4
4	The Upregulation of Caffeic Acid Phenethyl Ester on Growth Differentiation Factor 15 Inhibits Transforming Growth Factor β/Smad Signaling in Bladder Carcinoma Cells. Biomedicines, 2022, 10, 1625.	3.2	0
5	A doubleâ€blind, randomized, placeboâ€controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 108-117.	1.3	3
6	Mucosa-Associated Lymphoid Tissue 1 Is an Oncogene Inducing Cell Proliferation, Invasion, and Tumor Growth via the Upregulation of NF-ήB Activity in Human Prostate Carcinoma Cells. Biomedicines, 2021, 9, 250.	3.2	8
7	The Clinical Experiences of Urine Metabolomics of Genitourinary Urothelial Cancer in a Tertiary Hospital in Taiwan. Frontiers in Oncology, 2021, 11, 680910.	2.8	2
8	Clinical Outcome of Endoscopic Enucleation of the Prostate Compared With Robotic-Assisted Simple Prostatectomy for Prostates Larger Than 80 cm ³ in Aging Male. American Journal of Men's Health, 2021, 15, 155798832110641.	1.6	5
9	Proteomic characterization of arsenic and cadmium exposure in bladder cells. Rapid Communications in Mass Spectrometry, 2020, 34, e8578.	1.5	4
10	Antioxidation and Antiapoptosis Characteristics of Heme Oxygenase-1 EnhanceÂTumorigenesis of Human Prostate Carcinoma Cells. Translational Oncology, 2020, 13, 102-112.	3.7	8
11	Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer. Cancers, 2020, 12, 10.	3.7	21
12	Effect of ureteral calculus in outpatients receiving semirigid ureteroscope laser lithotripsy. Medicine (United States), 2020, 99, e19324.	1.0	3
13	Clinical outcome of transurethral enucleation of the prostate using the 120-W thulium Laser (Velaâ,,¢) Tj ETQq1 1888-1898.	l 0.78431 3.1	.4 rgBT /Ove 13
14	Gassless Single-Port Retroperitoneoscopic Surgery for Urologic Disease: Case Series Reports. Archives of Nephrology and Urology, 2020, 03, .	0.1	0
15	Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy. In Vivo, 2019, 33, 1249-1262.	1.3	5
16	Transgelin, a p53 and PTEN-Upregulated Gene, Inhibits the Cell Proliferation and Invasion of Human Bladder Carcinoma Cells in Vitro and in Vivo. International Journal of Molecular Sciences, 2019, 20, 4946.	4.1	20
17	Association between Bladder Outlet Obstruction and Bladder Cancer in Patients with Aging Male. Journal of Clinical Medicine, 2019, 8, 1550.	2.4	6
18	Migration and Invasion Enhancer 1 Is an NF-Äß-Inducing Gene Enhancing the Cell Proliferation and Invasion Ability of Human Prostate Carcinoma Cells In Vitro and In Vivo. Cancers, 2019, 11, 1486.	3.7	12

#	Article	IF	CITATIONS
19	Invasion of Adjacent Lumbar Vertebral Body from Renal Pelvis Carcinoma: Associated With Bone Metastasis But Easily Overlooked on Initial CT Scan. In Vivo, 2019, 33, 939-943.	1.3	3
20	Metallothionein 3 Is a Hypoxia-Upregulated Oncogene Enhancing Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells. International Journal of Molecular Sciences, 2019, 20, 980.	4.1	18
21	Inhibitory effect of berberine on interleukin-2 secretion from PHA-treated lymphocytic Jurkat cells. International Immunopharmacology, 2019, 66, 267-273.	3.8	17
22	The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells. Cell Proliferation, 2018, 51, e12429.	5.3	22
23	Transurethral resection of the prostate provides more favorable clinical outcomes compared with conservative medical treatment in patients with urinary retention caused by benign prostatic obstruction. BMC Geriatrics, 2018, 18, 15.	2.7	19
24	Capillarisin blocks prostateâ€specific antigen expression on activation of androgen receptor in prostate carcinoma cells. Prostate, 2018, 78, 242-249.	2.3	9
25	BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells. Cancer Medicine, 2018, 7, 184-195.	2.8	34
26	Transurethral resection of the prostate achieves favorable outcomes in stroke patients with symptomatic benign prostate hyperplasia. Aging Male, 2018, 21, 9-16.	1.9	10
27	An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin. Clinical Interventions in Aging, 2018, Volume 13, 235-242.	2.9	5
28	Caffeic Acid Phenethyl Ester Induces N-myc Downstream Regulated Gene 1 to Inhibit Cell Proliferation and Invasion of Human Nasopharyngeal Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 1397.	4.1	20
29	Anti-inflammatory Effects of Gossypol on Human Lymphocytic Jurkat Cells via Regulation of MAPK Signaling and Cell Cycle. Inflammation, 2018, 41, 2265-2274.	3.8	14
30	Pre-therapy CT scan showing peritoneal thickening from metastatic renal pelvis carcinoma patients. Medical Oncology, 2018, 35, 128.	2.5	2
31	Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis. Anticancer Research, 2018, 38, 3187-3192.	1.1	1
32	Caffeic acid phenethyl ester upregulates N-myc downstream regulated gene 1 via ERK pathway to inhibit human oral cancer cell growth in vitro and in vivo. Molecular Nutrition and Food Research, 2017, 61, 1600842.	3.3	27
33	Dose–Response Relationship between Inorganic Arsenic Exposure and Lung Cancer among Arseniasis Residents with Low Methylation Capacity. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 756-761.	2.5	24
34	ls diabetes mellitus associated with clinical outcomes in aging males treated with transurethral resection of prostate for bladder outlet obstruction: implications from Taiwan Nationwide Population-Based Cohort Study. Clinical Interventions in Aging, 2017, Volume 12, 535-541.	2.9	13
35	Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics. Oncotarget, 2017, 8, 38802-38810.	1.8	51
36	Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis. OncoTargets and Therapy, 2017, Volume 10, 2943-2949.	2.0	4

#	Article	IF	CITATIONS
37	The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo. International Journal of Molecular Sciences, 2016, 17, 1435.	4.1	41
38	Impact of the static prostatic urethral angle on men with lower urinary tract symptoms. Urological Science, 2016, 27, 47-50.	0.6	5
39	Treatment outcomes of benign prostate hyperplasia by thulium vapoenucleation of the prostate in aging men. Urological Science, 2016, 27, 230-233.	0.6	5
40	The impact of diabetes mellitus on patients receiving robotic assisted radical prostatectomy for prostate cancer. Urological Science, 2016, 27, S21.	0.6	1
41	Different laser prostatectomy for benign prostatic hyperplasia: What is the role of outcome-effectiveness analysis in clinical practice?. Urological Science, 2016, 27, 1-2.	0.6	0
42	Less pain perceived in transrectal ultrasound of prostate using microconvex transducer as compared to biplaned linear transducer. Urological Science, 2016, 27, 36-39.	0.6	1
43	Using a Harmonic Scalpel "Drilling and Clamping―Method to Implement Zero Ischemic Robotic-assisted Partial Nephrectomy. Medicine (United States), 2016, 95, e2349.	1.0	5
44	Economic Evaluation Study (Cheer Compliant) Laser Prostatectomy for Benign Prostatic Hyperplasia. Medicine (United States), 2016, 95, e2644.	1.0	8
45	Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells. Cancer Letters, 2016, 375, 142-151.	7.2	35
46	Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion and tumorigenesis in bladder carcinoma cells. Scientific Reports, 2015, 5, 12870.	3.3	49
47	Identifying the variables associated with pain during transrectal ultrasonography of the prostate. Patient Preference and Adherence, 2015, 9, 1207.	1.8	2
48	Divergent effect of liver X receptor agonists on prostateâ€specific antigen expression is dependent on androgen receptor in prostate carcinoma cells. Prostate, 2015, 75, 603-615.	2.3	13
49	Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer. Molecular and Cellular Proteomics, 2015, 14, 2466-2478.	3.8	62
50	Celastrol Blocks Interleukin-6 Gene Expression via Downregulation of NF-κB in Prostate Carcinoma Cells. PLoS ONE, 2014, 9, e93151.	2.5	49
51	Prostatic urethral angle might be a predictor of treatment efficacy of α-blockers in men with lower urinary tract symptoms. Drug Design, Development and Therapy, 2014, 8, 937.	4.3	6
52	The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis. OncoTargets and Therapy, 2014, 7, 1777.	2.0	0
53	Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Drug Design, Development and Therapy, 2014, 8, 1985.	4.3	7
54	Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer. OncoTargets and Therapy, 2014, 8, 15.	2.0	2

#	Article	IF	CITATIONS
55	Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Scientific Reports, 2014, 4, 5511.	3.3	27
56	Topoisomerase Inhibitors Modulate Gene Expression of B-Cell Translocation Gene 2 and Prostate Specific Antigen in Prostate Carcinoma Cells. PLoS ONE, 2014, 9, e89117.	2.5	9
57	Direct observation of procedural skills to improve validity ofÂstudents' measurement of prostate volume in predicting treatmentÂoutcomes. Urological Science, 2013, 24, 84-88.	0.6	2
58	Metallothionein 3: An androgenâ€upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. Prostate, 2013, 73, 1495-1506.	2.3	29
59	Mechanisms by Which Interleukin-6 Attenuates Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells. BioMed Research International, 2013, 2013, 1-11.	1.9	26
60	Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. Journal of Molecular Endocrinology, 2013, 51, 131-141.	2.5	34
61	Use of the SF-36 quality of life scale to assess the effect of pelvic floor muscle exercise on aging males who received transurethral prostate surgery. Clinical Interventions in Aging, 2013, 8, 667.	2.9	7
62	Prostatectomy using different lasers for the treatment of benign prostate hyperplasia in aging males. Clinical Interventions in Aging, 2013, 8, 1483.	2.9	14
63	Clinical outcome of primary small cell carcinoma of the urinary bladder. OncoTargets and Therapy, 2013, 6, 1179.	2.0	13
64	The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia. Clinical Interventions in Aging, 2013, 8, 265.	2.9	6
65	<scp>l</scp> -Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N- <i>myc</i> downstream regulated gene 1 in prostate carcinoma cells. American Journal of Physiology - Cell Physiology, 2012, 302, C676-C685.	4.6	51
66	Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells. Journal of Molecular Endocrinology, 2012, 49, 153-163.	2.5	41
67	1056 PROSTATE-DERIVED ETS FACTOR IS A TUMOR SUPPRESSOR GENE AND ASSOCIATED WITH EPITHELIAL-TO-MESENCHYMAL TRANSITION IN BLADDER CANCER. Journal of Urology, 2012, 187, .	0.4	Ο
68	Robotic assisted laparoscopic radical cystectomy for bladder carcinoma: early experience and oncologic outcomes. Formosan Journal of Surgery, 2012, 45, 178-182.	0.2	3
69	Glycoprotein transmembrane nmb: An androgenâ€downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells. Prostate, 2012, 72, 1431-1442.	2.3	23
70	Upregulation of prostateâ€derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. International Journal of Cancer, 2012, 130, 2812-2823.	5.1	52
71	Mechanisms by Which Interleukin-6 Regulates Prostate-Specific Antigen Gene Expression in Prostate LNCaP Carcinoma Cells. Journal of Andrology, 2011, 32, 383-393.	2.0	13
72	The outcome of a photoselective vaporization prostatectomy using a high-performance system to treat benign prostatic hyperplasia with acute urinary retention. Urological Science, 2011, 22, 151-153.	0.6	2

#	Article	IF	CITATIONS
73	Nonâ€inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU International, 2011, 108, 1843-1848.	2.5	58
74	p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate, 2011, 71, 62-70.	2.3	31
75	Curcumin provides potential protection against the activation of hypoxia and prolyl 4â€hydroxylase inhibitors on prostateâ€specific antigen expression in human prostate carcinoma cells. Molecular Nutrition and Food Research, 2011, 55, 1666-1676.	3.3	22
76	A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta Pharmacologica Sinica, 2011, 32, 537-542.	6.1	12
77	Bikunin Loss in Urine as Useful Marker for Bladder Carcinoma. Journal of Urology, 2010, 183, 339-344.	0.4	26
78	Cardiac Glycosides Decrease Prostate Specific Antigen Expression by Down-Regulation of Prostate Derived Ets Factor. Journal of Urology, 2010, 184, 2158-2164.	0.4	25
79	Efficacy and Safety of the Doxazosin Gastrointestinal Therapeutic System for the Treatment of Benign Prostate Hyperplasia. Kaohsiung Journal of Medical Sciences, 2010, 26, 532-539.	1.9	7
80	Discovery of Novel Bladder Cancer Biomarkers by Comparative Urine Proteomics Using iTRAQ Technology. Journal of Proteome Research, 2010, 9, 5803-5815.	3.7	137
81	Early Results of Photoselective Vaporization of the Prostate in Medical Controlâ€failed Patients. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 70-73.	1.3	1
82	LUTEOLIN AFFECTS CELL PROLIFERTATION, CELL INVASION AND PROSTATE-SPECIFIC ANTIGEN EXPRESSION BY DYREGULATION OF PROSTATE-DERIVED ETS FACTOR AND ANDROGEN RECEPTOR EXPRESSION IN PROSTATE CARCINOMA LNCAP CELLS. Journal of Urology, 2009, 181, 396-396.	0.4	0
83	Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the Bâ€Cell translocation gene 2. Prostate, 2008, 68, 610-619.	2.3	61
84	Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacologica Sinica, 2008, 29, 364-370.	6.1	33
85	Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells. Acta Pharmacologica Sinica, 2008, 29, 1334-1341.	6.1	11
86	Curcumin Blocks the Activation of Androgen and Interlukinâ€6 on Prostateâ€5pecific Antigen Expression in Human Prostatic Carcinoma Cells. Journal of Andrology, 2008, 29, 661-668.	2.0	52
87	GROWTH DIFFERENTIATION FACTOR-15 DECREASES TUMORIGENESIS AND INVASION IN PC-3 PROSTATE CARCINOMA CELLS. Journal of Urology, 2008, 179, 43-44.	0.4	0
88	Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line. Anticancer Research, 2008, 28, 1969-76.	1.1	14
89	Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. Anticancer Research, 2008, 28, 1977-83.	1.1	12
90	Laparoscopic radical prostatectomy: initial experience of robotic surgery in Taiwan. Anticancer Research, 2008, 28, 1989-92.	1.1	5

#	Article	IF	CITATIONS
91	Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. Anticancer Research, 2008, 28, 1993-9.	1.1	25
92	Can probability of genetic mutation be an indicator of clinical relevance?. Genomics, 2007, 90, 746-750.	2.9	3
93	Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian Journal of Andrology, 2007, 9, 711-715.	1.6	14
94	Arterial bleeding in patients with intractable hematospermia and concomitant hematuria: A preliminary report. Urology, 2006, 68, 938-941.	1.0	16
95	Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics, 2006, 6, 4381-4389.	2.2	33
96	Synchronous primary carcinomas of the bladder and prostate. Asian Journal of Andrology, 2006, 8, 357-359.	1.6	37
97	Manganese antagonizes iron blocking mitochondrial aconitase expression in human prostate carcinoma cells. Asian Journal of Andrology, 2006, 8, 307-315.	1.6	7
98	V-MitoSNP: visualization of human mitochondrial SNPs. BMC Bioinformatics, 2006, 7, 379.	2.6	17
99	Zinc blocks gene expression of mitochondrial aconitase in human prostatic carcinoma cells. International Journal of Cancer, 2006, 118, 609-615.	5.1	25
100	COMPLICATIONS FOLLOWING COMBINED TRANSRECTAL ULTRASOUND-GUIDED PROSTATE NEEDLE BIOPSIES AND TRANSURETHRAL RESECTION OF THE PROSTATE. Archives of Andrology, 2006, 52, 123-127.	1.0	6
101	Cholesterol modulation of the expression of mitochondrial aconitase in human prostatic carcinoma cells. Chinese Journal of Physiology, 2005, 48, 93-100.	1.0	5
102	PROBABILITY BASED DIAGNOSTIC BIOPSY SPECIMENS AS PREDICTORS OF TUMOR GRADE AND STAGE FOUND. Archives of Andrology, 2004, 50, 333-337.	1.0	5
103	DOWN-REGULATION OF THE PROSTATE SPECIFIC ANTIGEN PROMOTER BY p53 IN HUMAN PROSTATE CANCER CELLS. Journal of Urology, 2004, 172, 2035-2039.	0.4	17
104	IDENTIFYING THE COMBINATION OF THE TRANSCRIPTIONAL REGULATORY SEQUENCES ON PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN GENES. Journal of Urology, 2004, 172, 2029-2034.	0.4	20
105	Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology, 2004, 64, 839-844.	1.0	77
106	MINILAPAROTOMY RADICAL RETROPUBICPROSTATECTOMY FOR PROSTATE CANCER. Archives of Andrology, 2004, 50, 23-25.	1.0	4
107	HEMATURIA FROM LEFT INTERNAL PUDENDAL AND OBTURATOR ARTERIAL BLEEDING FOLLOWING SEXUAL INTERCOURSE. Archives of Andrology, 2003, 49, 453-455.	1.0	6
108	INTRACTABLE BLADDER TAMPONADE DUE TO LEFT INTERNAL PUDENDAL AND OBTURATOR ARTERIAL BLEEDING INDUCED BY ERECTION: A SUPERSELECTIVE ARTERIOGRAPHY FOLLOWED BY TRANSCATHETER ARTERIAL EMBOLIZATION. Archives of Andrology, 2003, 49, 361-363.	1.0	0

#	Article	IF	CITATIONS
109	Interstitial laser photocoagulation for treatment of benign prostatic hypertrophy: outcomes and cost effectiveness. Chang Gung Medical Journal, 2003, 26, 799-806.	0.7	3
110	IS ADRENALECTOMY A NECESSARY COMPONENT OF RADICAL NEPHRECTOMY? UCLA EXPERIENCE WITH 511 RADICAL NEPHRECTOMIES. Journal of Urology, 2000, 163, 437-441.	0.4	157
111	CL1-GFP: AN ANDROGEN INDEPENDENT METASTATIC TUMOR MODEL FOR PROSTATE CANCER. Journal of Urology, 2000, 164, 1420-1425.	0.4	53
112	Evaluation of a Decision-support System for Preoperative Staging of Prostate Cancer. Medical Decision Making, 1999, 19, 419-427.	2.4	14
113	EFFECTS OF IMPLEMENTATION OF 18 CLINICAL PATHWAYS ON COSTS AND QUALITY OF CARE AMONG PATIENTS UNDERGOING UROLOGICAL SURGERY. Journal of Urology, 1999, 161, 1858-1862.	0.4	24
114	The specific gallium-67 scan uptake pattern in psoas abscesses. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1442-1447.	6.4	11
115	THE EARLY EFFECT OF PELVIC FLOOR MUSCLE EXERCISE AFTER TRANSURETHRAL PROSTATECTOMY. Journal of Urology, 1998, 160, 402-405.	0.4	33
116	Improvement of Medical Care Quality after Implementation of a Clinical Path Monitoring Program for Transurethral Prostatectomy Patients. European Urology, 1998, 33, 523-528.	1.9	8